• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Cell Therapeutics

edit

Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin’s lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.

Milestones

edit

• 
  Cell Therapeutics added Louis A. Bianco as EVP, Finance and Administration.
  Posted 1/15/10 at 9:01pm
• 
  Cell Therapeutics added James A. Bianco as CEO.
  Posted 1/15/10 at 9:01pm
• 
  Went public with stock symbol NASDAQ:CTIC.
  Posted 1/15/10 at 9:01pm
• 
  Cell Therapeutics received $25M in Venture Round funding. (1/13/11)
  Posted 1/16/11 at 10:32pm via fiercebiotech.com
• 
  Cell Therapeutics received $21M in Venture Round funding. (5/24/10)
  Posted 5/24/10 at 7:55pm via fiercebiotech.com
• 
  Cell Therapeutics received $30M in Venture Round funding. (8/19/09)
  Posted 1/15/10 at 9:01pm via fiercebiotech.com
• 
  Cell Therapeutics — UPDATED: Cell Therapeutics lands myelofibrosis drug with $30M upfront (4/19/12)
  Posted 4/19/12 at 7:44pm via fiercebiotech.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/16/10

Stock Price

Sources

1. Cell Therapeutics stock sale raises $30M and eyebrows (fiercebiotech.com) [edit]
2. Struggling Cell Therapeutics raises $21M in stock sale (fiercebiotech.com) [edit]
3. Cell Therapeutics raises $25M (fiercebiotech.com) [edit]
UPDATED: Cell Therapeutics lands myelofibrosis drug with $30M upfront (fiercebiotech.com) [edit]